Pulmonary arterial hypertension in Latin America: epidemiological data from local studies

BMC Pulmonary Medicine

Table 1 Characteristics of PAH registries/studies included in the review

Characteristic	Argentina [29]	Brazil [7]	Chile [28]	HINPULSAR [21]	RECOPILAR [22]	Chile [27]
Study design and time period	Prospective January 2004–March 2012	Prospective January 2008–December 2013	1999–2005	Prospective January 2010–December 2011	Prospective July 2014 – May 2015	Prospective June 2003–March 2005
Number of centres	1	1	2	31	Multicenter^a	1
Study cohort	Group 1 PH	Group 1 PH	Group 1 PH	Group 1 PH	Group 1 PH	Group 1 PH and Group 4 PH
Percentage of patients with group 1 PH (number of PAH patients)	100% (125)	100% (178)	100% (17)	100% (124)	100% (170)	93% (27)
% IPAH patients	49	29	80	52	52	41
% CTD-PAH	14	26	13	15	15	26
% CHD-PAH	28	8	_	27	27	33
% Sch-PAH	_	20	_	_	_	_
% Others^b	9	18	7	6	6	_
% female	79	77	60	78	79	86
Mean age (years-old)	34 ± 16	46 ± 15	45	45 ± 17	51	41 ± 14
% FC III/IV	58	46	47	62	70	85
6MWD (m)	360	383 ± 152	348 ± 98	_	373	378 ± 113
RAP (mm Hg)	8	10 ± 5	12 ± 8	_	10	8 ± 7
mPAP (mm Hg)	54	52 ± 18	57 ± 15	55 ± 20	_	59 ± 12
PVR (woods units)	12	10 ± 6	_	_	_	_
CI (L/min/m²)	2	3 ± 1	2 ± 1	_	3	3 ± 1
Time from onset of symptoms until diagnosis (years)	1.4	_	_	_	_	2.9

CTD connective tissue disease, CHD congenital heart disease, Sch schistosomiasis-associated, FC functional class, 6MWD 6-minute walking distance, RAP right atrial pressure, mPAP mean pulmonary artery pressure, PVR pulmonary vascular resistance, Cl cardiac index
^aThe number of centres was not provided
^bOthers: PAH associated to drugs and toxins, associated to HIV and portal hypertension

ISSN: 1471-2466